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This year’s first issue is on Thrombosis and 
Haemostasis which is a complex physiological 
process occurring in the human body. Most 
researchers claim that it is two sides of the same 
coin. Bleeding and thrombotic disorders are common 
and challenging medical problems. A good bleeding/
haemostatic history will give you the diagnosis 
in majority of patients. Laboratory investigations 
then support your differential diagnosis. AKUH’s 
Clinical Laboratory offers a wide panel of bleeding 
and thrombophilia testing that can be effectively 
utilized in proper evaluation of the patients with 
haemostatic abnormalities. This issue is an attempt to 
provide physicians with information on haemostatic 
abnormalities that help in screening and diagnosing 
of these diseases. The issue includes articles on 
appropriate work-up of suspected bleeding disorder, 
transfusion-associated-viral infections such as HIV, 
hepatitis B and C in patients who require blood 
product support for treatment, investigations for 
thrombophilia, acquired bleeding disorders such as 
paroxysmal nocturnal haemoglobinuria etc.  We hope 
that our readers will gain in depth insight from this 
thematic issue.
Dr Natasha Ali
From the Editor’s Desk
Critical International Normalised Ratio
Dr Shabneez Malik
Haematology 
Oral anticoagulant therapy is commonly used in 
the management of venous thrombosis such as 
deep venous thrombosis of  veins and pulmonary 
embolism. 
Previously, laboratories used to report 
prothrombin time as a part of anticoagulation 
monitoring. It was then found out that the 
prothrombin time varied due to the difference 
in sensitivity of various thromboplastins 
used in different clinical laboratories. World 
Health Organization (WHO) devised the term 
“International Normalised Ratio” (INR) to 
reduce this inter-laboratory variability.This term 
is self-explanatory. This is a ratio of patient’s 
prothrombin time divided by reference normal 
prothrombin time to the power of a coefficient 
which is known as “international sensitivity 
index.” This relates the sensitivity of a given 
thromboplastin to the sensitivity of WHO’s 
first international reference preparation of 
thromboplastin (given an ISI of 1.0). 
Monitoring of INR is critical in warfarinised 
patients. Because of the narrow therapeutic INR, 
patients on warfarin are stabilised within a range 
of 2-3.  Elevated INR can lead to haemorrhagic 
complications on one hand while sub-therapeutic 
INR can result in thrombosis. Therefore accurate 
monitoring of INR is crucial in preventing 
bleeding and thrombosis. The goal of establishing 
critical INR is to alert the physician to a 
potentially life threatening bleeding or thrombosis 
requiring urgent intervention. Critical INR value 
needs to be established at local level as the line 
between therapeutic and critical INR is thin.  
The Seventh American College of Chest Physicians 
Conference on Antithrombotic and Thrombolytic 
Therapy recommended therapeutic intervention 
in oral anticoagulant patients who have an INR 
of 5.0 or greater. Therefore, critical INR in many 
laboratories is 5.0.  In 2000 College of American 
Pathologist survey, 166 laboratories (27 per cent) 
had chosen a critical INR of 5.0. Similarly an INR 
below 1.5 should be considered critical for a patient 
on oral anticoagulation as the patient is at risk for 
thrombosis.
At AKUH, an INR of 5.0 or above is considered 
critical. At this INR, the patient is contacted for 
clinical details including medications. Patients are 
advised to repeat INR and to consult their primary 
physicians on emergency basis.  
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Physical Examination
The underlying cause can be determined by carefully 
examining the patients. Usually low platelets or 
platelet dysfunction produce muco-cutaneous 
bleedings [Fig. 1] while clotting factor deficiency 
results in a cavity bleed for example within joints, 
abdominal cavity, muscle, etc. [Fig. 2].
 
Laboratory Investigations 
Certain pre-requisites should be met before 
collection of blood samples for lab tests. These 
are listed in Table 2. 
Bleeding is a very common symptom for which 
patients approach doctors. At the same time, 
bleeding disorders are a common reason for a 
general practitioner to consult a haematologist.
Determining the cause of bleeding disorders is 
challenging due to the variability of symptoms 
from patient to patient and requires a stepwise 
approach which traces each case from history 
to laboratory investigations. Questions usually 
focus on three main causes of bleeding: impaired 
vascular integrity, thrombocytopenia or platelet 
dysfunction and deficiency of clotting factors. The 
clinical manifestations of any bleeding disorder 
depend on the nature of defect and its severity.
History
How to Investigate a Bleeding Disorder?
Dr Natasha Ali
Haematology
Table 1.  Questions for a Patient Suffering from a Bleeding 
Disorder
Onset of bleeding – to distinguish between 
hereditary and acquired bleeding disorders
Type of bleeding – whether it is muco-cutaneous or 
within a cavity
Severity of bleeding – patient is asked whether 
the symptoms occur spontaneously or during 
haemostatic challenge e.g. surgical procedures, 
road traffic accidents, etc.
Frequency of bleeding.
Timing of bleeding episode – whether it occurs 
immediately or is it delayed.
Are other members in the family affected?
Drug history which particularly includes use of 
aspirin or NSAIDS
Nutritional history – deficiency of vitamin C
In case of an infant presenting with bleeding, 
ask the parents regarding prolonged bleeding 
during child’s circumcision or from his/her 
umbilical stalk
Fig. 1. Petechiae (small pinpoint cutaneous bleeding due to platelet defect 
or low platelets)
Fig. 2. Hemarthrosis in a Hemophilia patient – bleeding within the knee
joint secondary to defective coagulation
5VOL. 44, ISSUE 1JULY 2018
Screening tests: Any patient with a bleeding disorder 
should be tested for basic coagulation profile. The 
results of these will determine whether more specific 
tests are required for diagnosis. These tests are listed 
in Table 3.
Specialised tests: Based upon the screening test results, 
second line investigations are ordered for further work 
up. Different approaches are used to diagnose a patient 
depending on clinical details and screening tests. The 
four possible common scenarios are described below:
Case 1
If only PT is prolonged with normal platelet count 
and APTT, then factor VII deficiency should be 
suspected [Fig. 3]. Factor VII assay will help in 
establishing definitive diagnosis.
Case 2
If an isolated APTT elevation is observed and the 
patient has bleeding tendency then the APTT mixing 
test can help to differentiate between factor VIII and 
IX deficiency. Factor XI is also a remote possibility 
[Fig. 4]. Von Willebrand Disease can lead to raised 
APTT with elevated bleeding time. Presence of lupus 
anticoagulants or factor XII deficiency can increase 
APTT but patient will have no bleeding symptoms in 
this case.
Case 3
Combined elevation of PT and APTT raises the 
possibility of deficiencies of factors in common 
pathways such as I, II, V and X. Common causes 
are vitamin K deficiency in neonates or infants and 
liver disorders in adults. Anticoagulation therapy also 
leads to raised PT and APTT [Fig. 5].
PT-#
APTT-N
Platelet-N
No bleeding
Mild factor VII 
deficiency, Use of oral 
anticoagulants
Bleeding
Severe factor VII 
deficiency
Table 2. Pre-analytic Considerations for Coagulation Testing
Patient should not have received recent transfusions 
(blood, plasma products and platelets)
Patient  should not be on medications like Aspirin, 
NSAIDS or antibiotics (penicillin)
Patient should not be in stress (as it increases factor 
VIII levels)
Patient should not be pregnant (as it increases Von 
Willebrand factor antigen levels and factor VIII)
CBC including platelet count and peripheral film 
review
Bleeding time
Prothrombin time [PT]
Activated partial thromboplastin time [APTT]
Urea clot lysis test for factor XIII
Table 3 Screening Test for Investigating Bleeding Disorders
Fig. 3. Algorithm for Isolated Prolonged PT
Fig. 4. Algorithm for Isolated Prolonged APTT
Mild bleeding
vWD
PT-N
APTT- #
Platelet-N
Unprovoked
Injury related
Mild to moderate Hae-
mophilia A & B
Severe XI deficiency
Severe bleeding
Severe Haemophilia
Type III vWD
Fig. 5. Algorithm for Combined Elevation of PT and APTT
PT-#
APTT-#
Platelets-N
No bleeding
Mild deficiency of com-
mon pathways factors
Bleeding
Deficiency of common 
pathway factors. Combined 
factor V&VIII deficiency
Vitamin K deficiency
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Fig. 6. Algorithm for Eelevation of all Primary Screening Investigations.
Case 4 
Profound disturbance of primary screening results 
are indicative of global haemostatic abnormalities 
such as advanced hepatic disorder or disseminated 
intravascular coagulation (DIC) [Fig. 6].
In summary, while investigating a patient for 
suspected bleeding disorder, a thorough clinical 
history and physical examination is of paramount 
importance since majority of the disorders can 
be diagnosed with these two tools. Additionally, 
appropriate laboratory testing and timely 
consultation with a haematologist experienced in 
PT-#
APTT-#
Platelets-
No bleeding
Same causes
Bleeding
DIC Liver disease
Lupus anticoagulants
dealing with bleeding disorders are the key features 
of successful management of these patients.
Nucleic Acid Testing at AKUH
In recent years, despite improvements in serological 
tests for HCV, HBV and HIV infections, instances of 
viral transmission via transfusion still occur because 
of donations that take place while a donor is either 
in the pre-seroconversion window phase, infected 
with immunovariant viruses, or a non-seroconverting 
chronic carrier.
What is Nucleic Acid Testing and how does it help?
Nucleic Acid Testing, (NAT) is a highly sensitive 
molecular method of testing blood donations for 
viral nucleic acid. It is used to detect low level of 
viral genetic material present in the blood specimen 
even before the body begins producing antibodies in 
response to the virus. 
NAT significantly reduces the ‘window period,’ 
which is the time between donor exposure to the 
virus and the appearance of antibodies [Fig 1]. By 
reducing the window period it further diminishes 
occurrence of disease transmission via transfusion. 
The performance of the NAT assay is essentially 
dependent on both its analytical and clinical 
sensitivity and specificity. The analytical sensitivity 
is generally determined by testing dilutions of 
standardised materials such as WHO International 
Standards and subsequent calculations of 95 per 
cent Limit of Detection (LOD).  A NAT can be 
conveniently performed on a mini-pool which is a 
pool of six test samples.
Countries that have introduced NAT have 
encountered a decrease in residual risk of viral 
transmissions. Although other safety measures such 
as more stringent selection of blood donors have 
contributed as well as a marked decrease is evident 
between pre- and post-NAT implementation. The 
residual risk for HCV transmission prior to NAT 
was 0.64 cases per million in France and 3.94 per 
million in Spain which decreased to 0.1 per million 
and 2.33 per million respectively after NAT was 
adopted. HIV NAT yield rates were estimated at 
0.3 per million donations in France and Spain as 
opposed to 0.59 and 2.48 respectively preceding 
NAT incorporation. There is potential that next 
generation NAT testing could completely eradicate 
transfusion risk of HIV, HCV and HBV.
Sana Chundrigar 
Molecular Pathology
Fig. 1. Window period of HIV, HCV and HBV    
11 days 25 days
12 days 75 days
Detection of HIV I and II         
Detection of HCV         
Detection of HBV         
25 days 60 days
NAT testing
Ag & Ab Detection
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1. Lysis, stabilisation     2. Capture  3. Wash   4. Elute
and deproteination
NAT at AKUH
The quality of blood products at the AKUH has further 
improved by the recent addition of NAT testing in the 
blood donor screening programme. There is automated 
pooling of blood donations, sample preparation, 
amplification (real time polymerase chain reaction or 
PCR) and detection. [Fig.2]. 
Before authorising for general use the NAT 
test was validated on more than 1000 blood 
donations. So far up to 18,000 blood donations 
have been screened by NAT assay and 
unsurprisingly it has captured many window 
period positive specimens. 
Fig. 2.  Steps in Nucleic Acid Extraction 
Real time data collection allows monitoring of 
the PCR process in each individual cycle instead 
of end point measurement after completion of all 
cycles [Fig.3].
Fig. 3. Principles of the Real Time PCR
Lab Diagnosis of von Willebrand Disease
Von Willebrand Disease (VWD) is an autosomally 
inherited congenital bleeding disorder resulting 
from deficiency or dysfunction of von Willebrand 
factor (VWF). The predominant clinical problems 
are muco-cutaneous bleeds. Therefore, patients 
usually present with petechiae, oral and gum 
bleeding, nose bleeding or epistaxis. Excessive 
menstrual loss or menorrhagia is a common 
bleeding problem in women of reproductive 
age. Circumcision acts as a good haemostatic 
challenge in case of males and therefore boys may 
be diagnosed earlier than girls. VWD has three 
clinical types based on von Willebrand Antigen 
(VWAg) levels.
Laboratory assessment for Von Willebrand Disease
Following are the laboratory tests which should be 
performed for the laboratory diagnosis of VWD. 
Bushra Afaq and Dr Bushra Moiz
Haematology
Bleeding time: It is performed by IVY method. Its   
reference range is between 1-6 minutes
APTT: A clotting assay having a reference range 
between 25-35 seconds.
VWAg: A quantitative determination of von 
Willebrand activity by turbidimetric method. Its
reference range is between 50-160 per cent.
F-VIII: A clotting assay having a reference range 
between 50-150 per cent.
R-COF: A quantitative determination of F-VIII 
Ristocetin Cofactor activity using aggregometry 
technique. Its reference value is >40 per cent.
RIPA: Ristocetin platelet induced aggregometry. 
Normal platelets show response to standard strength 
of ristocetin but fail to respond to a lower dose.
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AKUH’s Clinical laboatory offers a variety of tests required for diagnosis and characterisation of VWD. 
Results of the above stated laboratory tests are summarized in the Table 1.
   Decreased activity in comparison to reference range
#  More than normal range
N   Normal
L    Subnormal activity
Normal Type 1 Type 
2A
Type 
2B
Type 
2M
Type 
2N
Type 3 PLT-
VWD
VWF:Ag N
N
N
N
N
N
VWF:RCo
FVIII
RIPA
BT
Platelet
Count
L or 
L or 
N or 
often N
N or #
N N N or  N N N 
# # N N # #
 often N  N often Nabsent
N or  N or  N or   1-9 IU/dL N or L
   N or L absent 
or L or L or L N or L absent or L
Table 1. Expected Laboratory Values in Subtypes of VWD
Scoring Systems in Diagnosis of Disseminated 
Intravascular Coagulation 
Dr Natasha Ali 
Haematology
The liver is the most important organ involved 
in the regulation of haemostasis. Most of the 
clotting factors, their inhibitors and a number of 
proteins responsible for fibrinolysis are produced 
in the liver. Therefore, liver disease impacts both 
primary and secondary haemostasis pathways 
through a number of different mechanisms. 
Abnormalities of the clotting cascade are the 
predominant features of acute and chronic liver 
disease. In some patients suffering from hepatic 
disease, physicians are faced with the diagnostic 
challenge of an underlying bleeding or thrombotic 
diathesis due to overlap between various clinical 
syndromes including Disseminated Intravascular 
Coagulation (DIC).
According to the International Society of Thrombosis 
and Haemostasis (ISTH), DIC is a syndrome 
characterised by a systemic intravascular activation 
of coagulation, with loss of localisation, arising from 
different causes. It can originate from and cause 
damage to the microvasculature, which if sufficiently 
severe can produce organ dysfunction. ISTH also 
proposed that the working definition of DIC can be 
divided into two phases:
a)   Non-overt DIC: represents subtle haemostatic 
 dysfunction
b)   Overt DIC: de-compensated phase of non-overt 
 DIC
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more is considered to be compatible with DIC, 
whereas a score of 
less than five may be indicative (but not 
affirmative) for non-overt DIC. Similarly using 
certain clinical and laboratory findings [Table 
2] a score of five or greater is compatible with 
non-overt DIC and could diagnostically define 
patients with a poor prognosis due to haemostatic 
dysfunction, independent of developing overt 
DIC. 
Following steps are suggested for the diagnosis 
of DIC:
Step 1: Determine if the patient has an underlying 
condition associated with DIC. If no underlying is 
present then do not proceed further.
Step 2: Order screening coagulation tests and 
decide whether patient has overt or non-overt 
DIC.
Table 1. ISTH Score System for Overt DIC
Screening Tests Findings Points
PLATELET COUNT >100,000/µL  0
 50,000-100,000/ µL  1
 <50,000/ µL  2
PROTHROMBIN (PT upper limit of reference 
TIME range) >3 secs  0
 (PT upper limit of reference range) 
 =3-5.9 secs  1
 (PT upper limit of reference range) 
 ≥6 secs  2
FIBRINOGEN >100mg/dl  0
 <100mg/dl  1
FIBRIN MONOMER No increase  0
 Moderate increase  2
 Severe increase  3
Table 2. ISTH Score for non-Overt DIC
Parameter Findings Points
Diagnosis Not associated with DIC  0
 Associated with DIC  2
Platelet count >100,000/µL  0
 <100,000/µL  1
Prolongation of PT < 3 seconds  0
 > 3 seconds  1
Soluble fibrin or FDP Normal  0
 Increased  1
Antithrombin III Normal    -1
 Low  1
Protein C Normal    -1
 Low  1
Events responsible for DIC in liver disease include 
liver necrosis, impaired endotoxin clearance, 
surgery, shock and ascites recirculation. DIC can 
be recognised as a syndrome suggested by clinical 
signs and laboratory tests. The characteristic 
laboratory findings include: prolonged prothrombin 
time (PT), activated partial thromboplastin time 
(APTT), thrombin time (TT), increased levels of 
fibrin related markers (fibrin degradation products, 
D-Dimer), decreased platelet count, fibrinogen level, 
plasma coagulation factors and their inhibitors. More 
specialised and useful tests include: prothrombin 
activation fragments and thrombin-antithrombin 
complex (TAT).
In 2001, ISTH proposed two separate scoring 
systems for overt and non-overt DIC. The overt 
DIC score consists of a five steps diagnostic 
algorithm, in which a specific score, reflecting the 
severity of the abnormality found, is given to each 
of the laboratory tests [Table 1]. A score of five or 
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Ristocetin Cofactor Activity
Ristocetin Cofactor (RCo) measurement is essential 
for the diagnosis of von Willebrand disease (VWD). 
VWD is an autosomally-inherited congenital 
bleeding disorder that is caused by deficiency or 
dysfunction of von Willebrand factor (VWF), a 
plasma protein that mediates the initial adhesion 
of platelets at site of vascular injury and also binds 
and stabilises blood clotting factor VIII (FVIII) 
in the circulation. Therefore, defects in VWF can 
cause bleeding by impairing platelet adhesion or by 
reducing the concentration of FVIII. 
VWD is classified into three major categories: 
1. Type 1: a  quantitative deficiency of VW 
 factor (<30 per cent)
2. Type 2: a qualitative defect of VWF having 
 dysfunctional proteins. Type 2 has further
 subtypes (2A, 2B, 2M, 2N) based on   
 laboratory tests. 
3. Type 3: a severe deficiency of VWF (<3 per cent)
The RCo Assay is used in the quantitative 
determination of RCo activity in citrated plasma. 
It is particularly useful in detection of type 2A, 
2B, and 2M VWD, where the VWF: Ag may be 
normal or near normal whereas the VWF: RCo is 
markedly reduced.
RCo Activity in plasma may be determined by 
the agglutination of a standardised suspension of 
platelets in the presence of von  Willebrand factor 
using the antibiotic called Ristocetin. The RCo 
Activity is the in-vitro activity of the von Willebrand 
factor, which is responsible for the agglutination 
of platelets in the presence of Ristocetin. Levels of 
RCo activity are determined by the ability of the test 
plasma and Ristocetin to induce aggregation in a 
standardised platelet suspension.
Principle of the test method is reconstituted 
lyophilised platelets are treated with Ristocetin in the 
presence of varying dilutions of normal standardised 
human plasma having known amounts of RCo 
Activity. A standard curve is thus prepared. Patient 
Bushra Afaq
Haematology
Fig. 1. Standard Curve and Interpolation of Ristocetin Cofactor Activity for the Patient  
plasma is then tested in the presence of Ristocetin 
and reconstituted platelets and an aggregation 
pattern is determined. RCo Activity of test plasma is 
interpolated from the standard curve [Fig. 1].
Results of less than 40 per cent RCo (von 
Willebrand Factor) are generally considered 
abnormal and are indicative of von Willebrand 
disease.
As a quality control of deficient von Willebrand 
Reference Plasma is included in the test kit to 
function as an abnormal Control. The RCo value of 
this Control is less than 30 per cent.
The RCo assay is considered by many investigators 
to be the single most important assay for VWD. 
However, a complete diagnosis and determination 
of the variant forms of this coagulopathy requires an 
evaluation of family history and lab parameters such 
as Von Willebrand antigen, Factor VIII activity and 
bleeding time.
The test is available at Aga Khan University 
Hospital’s clinical laboratory.
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What is Thrombophilia?
Heritable thrombophilia is an increased tendency 
towards venous thrombosis. Initially the terminology 
was reserved for inherited disorders only but later 
the term ‘thrombophilia’ was used loosely for both 
inherited and acquired disorders with a predisposition 
for either venous or arterial thrombosis.
Assessment of Thrombophilia
1. Clinical: Assessment of thrombophilia starts 
 with detailed clinical history and physical 
 examination. The patient should be assessed 
 for acquired risk factors, medication and co-
 morbids.
2. Laboratory: The tests are listed in Table 1. 
 All the mentioned tests are offered by the 
 clinical laboratory at AKUH.
All You Need to Know About Thrombophilia 
Screening
Dr Bushra Moiz
Haematology
Selection of Patient for Heritable Thrombophilia
The inherited thrombophilia screening in an unselected 
patient population is not advisable. Since it is genetic, 
testing with personal and family considerations 
therefore patients should be carefully chosen. Not every 
patient with thrombosis requires this testing. Table 2 
and 3 summarise the conditions in which screening 
should not be performed. The information provided 
is according to the guidelines published by the British 
Committee of Standards in Haematology.  
What are the Appropriate Timings of Testing?
There is seldom any point in striving to obtain 
samples for thrombophilia testing when the patient 
presents with deep venous thrombosis (DVT) 
or pulmonary embolism (PE).  During an acute 
thrombotic episode, patients usually have low levels 
of protein C, protein S and antithrombin III
Table 1. Comprehensive Panel of Thrombophilia Testing
Routine
CBC, PT, APTT, Liver function tests 
and Serum creatinine
Protein C, protein S, anti-thrombin III,
activated protein C resistance(APCR)
Anticardiolipin antibodies (IgM and 
IgGO), lupus anticoagulants, 
serum homocysteine levels   
PNH screening (CD55and 59)
HIT
ADMATS-13 assay
JAK-2 V617F mutation
Specialised
Ancillary 
To determine safety profile before initiation of 
heparin and warfarin
Required in investigation of heritable 
thrombophilia
Required in acquired thrombophilia
Required for suspected PNH (intravascular 
haemolysis and pancytopenia)
For suspected HIT (heparin induced   
thrombocytopenia)
Needed for suspected TTP (micro-angiopathic 
haemolytic anaemia, thrombocytopenia, renal 
insufficiency and neurological deficit)
For suspected myeloproliferative disorder (MPD) 
with erythrocytosis/leucocytosis/thrombocytosis
PurposeTest
12
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Table 2. Conditions Recommended  for Thrombophilia Screening
Venous thrombosis at an early age ( <40 years) 
Venous thrombosis in  a patient with thrombosis prone family ( >2 symptomatic family members)
Neonates and children with  fulminating purpura (purpura fulminans) for protein C and S
Adults with skin necrosis following warfarin therapy for protein C and S
Case finding of asymptomatic relatives for high risk such as protein C and S deficiencies  in thrombosis 
prone families
Women requiring contraceptives or hormone replacement therapy with high risk thrombophilia in symptom-
atic relative
Pregnancy with previous travel related thrombosis
Asymptomatic pregnant woman with family history of thrombosis which was either unprovoked or provoked 
by pregnancy, combined oral contraceptives (COC) exposure or  traveling
Unselected patients with first episode of thrombosis
First episode of cerebral venous thrombosis
Arterial thrombosis
Paediatric stroke
Hospital acquired venous thrombosis
Asymptomatic relatives of low risk thrombophilia (factor V Leiden, prothrombin gene mutation).
Retinal vein occlusion
First event of an intra-abdominal vein thrombosis
Pregnant women with previous unprovoked thrombosis
Pregnancy with previous  trauma/surgery related thrombotic event
Pregnancy or COC related thrombosis
Unselected patients with upper limb thrombosis
Central Venous Catheters  related thrombosis
Table 3. Conditions Which Should not be Tested for Heritable Thrombophilia
13
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as the two are consumed in an attempt to natural 
thrombolysis. This results in false low levels 
of these proteins. Testing should be delayed 
for at least one month after discontinuation of 
oral anticoagulation. Pregnancy and oestrogen 
reduce protein S levels significantly and increase 
resistance to APC. If possible, thrombophilia 
testing should be avoided in inter-current illnesses, 
pregnancy and with oral contraceptive usage.
How should I collect Blood Samples?
The blood sample should be collected in standard 
sodium citrate bottle/blue top vacutainer in a ratio 
of 9:1 for lupus anticoagulant, protein C, S, APC, 
and AT-III. EDTA blood sample is required for HIT, 
PNH and JAK-2. Clotted blood sample is needed for 
anticardiolipin antibodies and homocysteine.
Methodology assays used at AKUH Clinical 
Laboratory
At AKUH, functional assays are used for heritable 
thrombophilia which have acceptable accuracy and 
precision. Table 4 shows the various tests and their 
methodologies used at AKUH.
How should I Interpret the Tests?
The thrombophilia screening should be supervised 
by experienced laboratory staff and the clinical 
significance should be made in consultation with an 
experience haematologist who is aware of relevant 
factors that may affect test results in each case. The 
factors affecting thrombophilia testing resulting in 
spurious assessment is listed in Table 5.
Do I need Repeating the Tests?
Repeat testing for protein C, S and anti-thrombin III 
is indicated and a low level should be confirmed on 
one or more separate samples. Diagnosis of deficiency 
should not be made on a single abnormal test.
Would the Testing affect Patient Management?
Initiation and intensity of anticoagulation 
following diagnosis of acute venous thrombosis 
in a patient should be the same with or without 
thrombophilia. Testing of thrombophilia in 
selected patients with strong family history of 
unprovoked thrombosis may influence decision 
regarding duration of anticoagulation.
Table 4. Tests and their Methodologies Used at AKUH Clinical Laboratories
Clinical utility Method
Heritable thrombophilia
Protein C
Protein S
Antithrombin III
APCR
Lupus anticoagulant
Anticardiolipin antibodies
Serum homocysteine
Acquired thrombophilia
Chromogenic assay
Clotting based assay
Chromogenic assay
Clotting based assay
Clotting based assay
ELISA
Immunogenic microparticulate 
assay
Tests
PNH
HIT
TTP
MPD
PNH screening
HIT screening
ADAMTS-13
JAK-2  V 617 F
Gel immunoassay
Gel immunoassay
ELISA
PCR
14
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 Table 5. Conditions Giving Rise to Misleading Results in Thrombophilia Screening
Acute thrombosis
Anticoagulants- heparin and warfarin
Direct thrombin inhibitors e.g. argatroban, lepirudin, bivalirudin
Liver disease
Pregnancy and COC
A Disintegrin and Metalloprotease with 
Thrombospondin Type 1 Motif, 13 (ADAMTS-13) 
is an enzyme which is released primarily from the 
stellate cells of the liver but is also found in platelets 
and endothelial cells. It is involved in the regulation 
of the size of von Willebrand factor (VWF) in 
plasma. 
ADAMTS-13 maintains primary haemostasis by 
proteolysing ultra-large von Willebrand Factor 
(ULvWF). The latter is the hyperactive form  of  
vWF which is released  from  storage  granules 
(Weibel-Palade bodies)  of  endothelial  cells  in 
response to inflammatory stimulation. The ULvWF 
has more affinity for platelets favouring platelet 
aggregation at sites of high shear stress with 
subsequent formation of micro vascular thrombi. The 
ULvWF relies upon ADAMTS-13 for its cleavage 
and its conversion into a less active form.
Deficiency of ADAMTS-13 may be congenital 
(Upshaw-Schulman syndrome) or more often 
than not acquired. An acquired deficiency is 
attributed to the presence of auto-antibodies 
against ADAMTS-13 which may either inhibit 
ADAMTS-13 function  or  may  cause  rapid  
clearance  of circulating  ADAMTS-13.  Inherited 
or acquired deficiency of ADAMTS-13 impairs 
ULvWF cleavage. Deficient proteolysis of ULvWF 
results in disseminated  platelet-rich  thrombi  in  
the microcirculation  which  in  turn  cause  typical 
thrombotic  micro-angiopathies  resulting  in  end 
organ ischemia.
The laboratory assessment of ADAMTS-13 levels 
is useful since severe deficiency of ADAMTS-13 
has been proposed as a specific laboratory marker 
of thrombotic thrombocytopenic purpura (TTP) 
or Upshaw-Schulman syndrome. It is also seen in 
conditions like sepsis, disseminated intravascular 
coagulation (DIC) and metastatic malignancy.  
Mild to moderate deficiency is seen in chronic 
inflammation, hepatic dysfunction and pregnancy.
Given  that  severe  secondary  deficiency  of 
ADAMTS-13 might correlate with development of 
widespread microvascular  thrombi and end organ 
injury, determination of ADAMTS-13 activity at 
the time of hospital admission in patients with 
severe conditions  like  sepsis  and  DIC  will  
help  in understanding the extent of the disease.  
It also raises the possibility of novel supportive 
therapies for patients with sepsis and DIC such as 
ADAMTS-13 supplementation and plasma therapy 
because sepsis may have the same pathophysiology 
of severe ADAMTS-13 deficiency for thrombotic 
microangiopathies as idiopathic TTP.
The test is currently offered by clinical 
laboratories of AKUH. It is based on the principle 
of enzyne linked immuno sorvent assay (ELISA) 
technique. Two to three millilitres of blood 
collected in citrate anticoagulant is required for 
the test. The reference range developed at AKUH 
for ADAMTS-13 is 175-365 ng/dl.  There is no 
difference in reference range between males and 
females or adults and children.
Utility of ADAMTS-13 Assay
Dr Farheen Karim Mahar 
Haematology 
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Elevated plasma homocysteine is associated with 
increased incidences of cardiovascular mortality, 
stroke, dementia and Alzheimer’s disease, bone 
fracture and higher prevalence of chronic heart 
failure. It was also shown that elevated plasma 
homocysteine is a risk factor for preclampsia and 
neural tube defects (NTD). Homocysteine has been 
implicated in atherosclerotic and thrombotic vascular 
disease in the general and in end-stage renal disease 
(ESRD) population as well.
Homocysteine is a sulphur containing amino acid, 
formed normally during metabolism of another        
sulphur containing amino acid methionine. It is 
metabolised by pathways, remethylation and trans-
sulfuration of methionine (Fig 1). Approximately 50 
per cent of methionine is metabolised to cystathioinine 
by cystathionine beta synthesase (CBS). This is 
a one way reaction that permanently removes 
homocysteine from the methionine cycle and initiates 
the transsulfuration pathway for methyl group either 
from N5 mehyltetrahydrofolate (in all tissues) or from 
betaine (in liver and kidneys) to form methionine. The 
former methylation step requires folate and vitamin 
B12 as cofactors in trans-sulfuration pathways and 
is effective when there is excess of methionine or 
cysteine synthesis is required.
Homocysteine as a Risk Factor of Thrombosis
Rakhshanda Maher  
Chemical Pathology
An elevated plasma homocysteine level has been 
found in patients with thrombotic disorders. In actual 
thrombosis is a formation of blood clot inside the 
blood vessel, obstructing the blood flow through the 
circulating system. It is mainly classified into venous 
and arterial thrombosis. The mechanism by which 
homocysteine contributes to atherothrombosis is 
complex and in vivo relevance is uncertain. However 
in the Journal of Clinical Investigation-2009, 
Jacoviner and his colleagues have reported a unique 
mechanism in vivo by which homocysteine may 
contribute to vascular disease. Accordingly, there is 
impairment in the synthesis of endothelial surface 
plasminogen which is the major fibrinolytic agent. 
This leads to micro vascular dysfunction and 
subsequent macro vascular occlusion in individuals 
with hyperhomocystenemia.
Most studies so far have indicated normal 
plasma homocystiene level to be in the 
range of 5 to 15 ul/L. However this does not 
imply that there is no risk associated with 
homocystiene levels between 10 to 15µl/L.
In 1990, the cut-off for homocysteine was 
greater than 20µmole/L. This number 
continued to go lower, and today, a level 
somewhere around 12µmole/L is considered 
as the recent cut-off. Homocysteine analyses 
in The National Health and Nutrition 
Examination Survey III (NHANES)  results 
shed some light into what constitutes ‘normal’ 
homocysteine levels in the US population. 
A study conducted in 1999 by NHANES 
investigators (published in Ann Intern Med 
1999; 131:331) showed that homocysteine 
levels continue to increase as a person ages, and men 
have a higher mean concentration than women.
The AKUH Clinical Laboratory in Karachi, measures 
the quantitative anticardiolipin IgG & IgM are 
measured using the DIASTAT anti-cardiolipin kit by 
indirect enzyme immunoassay method. The ACA panel 
includes only IgG and IgM antibodies.The incidence of 
IgA ACA is extremely low and their determination is 
not helpful in the investigation of thrombosis or other 
manifestations of the APLA syndrome.
Fig. 1. Metabolism of Homocysteine
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CD55 and CD59 for the Diagnosis of PNH
Paroxysmal nocturnal hemoglobinuria (PNH) 
is an acquired clonal hematopoietic stem cell 
disorder induced by exposure to chemicals or 
certain antibiotics and characterised by chronic 
intravascular haemolysis, venous thrombosis, 
defective haematopoiesis, frequent episodes of 
infection and rarely, leukemic transformation.
Pathophysiology of PNH
Patients with PNH have a defective gene 
called PIG-A, involved in the biosynthesis of 
glycosylphosphatidylinositol (GPI).Without 
GPI, important regulatory proteins (e.g. CD55 
or “DAF” and CD59 “MIRL”) cannot bind to 
the surface and protect blood cells from attacks 
of various proteins called complements. This 
may result in a breakdown of erythrocytes and 
release of haemoglobin which causes the urine 
to turn dark during an episode (or “paroxysm”) 
of haemolysis, though this is not found in all 
cases.
There are certain diagnostic tests which are 
used in the diagnosis of PNH including Ham’s 
test, sucrose lysis test, and CD55 and CD59 
analysis by flow cytometry and by using gel 
card technique.
CD55 and CD59 determination by gel card 
technique
 
Gel agglutination assay for PNH is a simple 
method for screening red cells for deficiency 
of GPI linked protein. For optimal results, 
the determination should be performed using 
a freshly drawn blood sample preferably 
into EDTA, citrate or heparin, CPD-A 
anticoagulant.
Fatima Azra Ausat
Haematology
Gel card tubes contain monoclonal antibodies 
against CD55 and CD59; if cells express both 
antigens the cells agglutinate by forming 
antigen antibody complexes and bind the 
mouse antibodies. After centrifugation through 
the gel, cells carrying antibodies, confirming 
the presence or MIRL or DAF, will show 
a positive reaction, grade three-four in the 
micro-tubes indicates the presence of a normal 
cell population. Cells deficient in MIRL or 
DAF show a negative reaction as a compact 
button at the bottom of the micro tube [Fig.1]. 
Double population of cells indicates a weak 
positive PNH test. Whenever it is necessary 
to know the amount of cells affected, a 
quantitative test procedure such as flow 
cytometry should be performed following a 
positive ID-PNH test.
PNH is only diagnosed where both MIRL and 
DAF are shown to be deficient.
Fig. 1. Gel card showing results for a normal person (three gel tubes on the 
left) and from a patient suffering from PNH (three gel tubes on the right)
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Detection of Heparin/Platelet Factor 4 Antibodies
Heparin-induced thrombocytopenia (HIT) is the 
development of thrombocytopenia due to the 
administration of Heparin. HIT predisposes to 
thrombosis and when thrombosis is identified 
the condition is called “Heparin-induced 
thrombocytopenia and thrombosis (HITT).” Clinical 
features associated with HIT syndrome primarily 
include a decreased platelet count, risk of venous 
or arterial thromboembolic complication and the 
development of antibodies against a complex of 
heparin and PF4. HIT is a life and limb threatening 
condition. The diagnosis is made on clinical suspicion 
requiring laboratory confirmation. The testing is 
recommended in all patients whose platelet count drop 
by 50 per cent of baseline within three to five days 
of heparin administration. HIT is observed both with 
unfractionated heparin and with low molecular weight 
heparin though the risk is less with latter.
Several tests are available for detection of Heparin/
PF4 antibodies in the laboratory [Table 1].  Aga 
Khan University Hospital, Clinical Laboratory 
uses ID-PaGIA Heparin/PF4 Antibody Gel Test for 
detection of these antibodies against this complex. 
Safia Naz
Haematology
The ID-PaGIA Heparin/PF4 antibody test is a particle 
gel immuno assay (PaGIA). High density synthetic 
polymer particles are coated with heparin/platelet 
factor 4 complex (HPF4). When these particles are 
mixed with patient serum-specific antibodies of any 
immunoglobulin class, they react with the HPF4A on 
the bead surface, causing agglutination. When  the 
reaction mixture is centrifuged through a gel filtration 
matrix, agglutinated particles are trapped on top of 
the gel or distributed within the gel (positive reaction) 
while free or  non- agglutinated particles form a pellet 
at the bottom of the micro tube (negative reaction). 
Due to the strong red colour of these particles, the 
result can be read visually with ease [Fig.1]. 
Fig. 1. Heparin/HP4 Gel Card showing Negative results for Patient One 
and Two and Positive results for Patient Three and Four.
Table 1. Recommendation for laboratory Testing for Heparin Induced Thrombocytopenia Antibodies
Test
Particle gel immunoassay 
ID-Heparin/PF4 antibody 
test (ID-H/PF4)
Enzyme linked 
immunosorbent assay 
test (ELISA)
Platelet aggregation test
Serotonin release 
assay/washed platelets 
activation assays
Methodology
Patient serum and PF4 heparin-coated micro-beads are added to the incubation 
chamber of the micro-column card and after five minutes, the card is 
centrifuged. A strong positive result indicated by the agglutinated micro-beads 
remaining top of the column.
It detects all circulating antibodies that bind Heparin PF4 complexes and may 
also falsely identify antibodies that do not cause HIT. Therefore, ELISA is more 
sensitive but less specific requiring further testing.
Citrated platelet rich-plasma is used as an initial test for HIT, a positive result 
generally supports the diagnosis of HIT and further testing is not required. 
However negative test does not exclude HIT in a patient with a moderate or 
high pre-test probability for HIT. In this situation washed platelets activation 
assay should be performed.
SRA is considered to be gold standard and is specific for the HIT antibodies. 
The platelets are washed and mixed with serum and heparin. The sample is then 
tested for the release of serotonin, a marker of platelet activation. If serotonin 
release assay shows high serotonin release, the diagnosis of HIT is confirmed.
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of LMWH. Blood sample should be delivered to the 
laboratory immediately or else falsely low values 
may occur (because platelets release platelet factor 
4 (PF4) which can neutralise heparin or LMWH). 
For the same reason, plasma must be separated from 
cells as soon as possible, ideally within one hour of 
specimen collection. Plasma can be stored for two 
hours at room temperature or can be frozen for later 
testing.
Laboratory is specifically notified as to which drug 
should be measured (heparin, LMWH). Limitations 
of this test include cost issues and less ready 
availability than the activated partial thromboplastin 
time (APTT) for heparin monitoring.
Patients not on anticoagulants: 0 unit/ml. 
Therapeutic range for anti-factor Xa for a deep 
venous thrombosis (DVT) patient differs according 
to the type of preparation used.:
Table 1. Reference Ranges for Anti-Factor Xa
Heparin: 0.3-0.7 units/ml
LMWH: 0.4-1.1 units/ml for twice daily 
subcutaneous dosing. For once daily 
subcutaneous LMWH dosing, the therapeutic 
range is less certain but is approximately 1-2 
units/ml.
Target range for DVT prophylaxis (prevention): 
There is no defined target range for prophylaxis 
of deep vein thrombosis DVT because such 
anticoagulation is not usually monitored. When 
anti-Xa levels have been measured, mean 
values are usually <0.45 units/ml.
Therapeutic range UFH: 0.3-0.7 U/L
Therapeutic range LMWH: 0.5-1.0 U/L
Prophylactic range UFH : 0.1-0.29 U/L
Prophylactic range LMWH: 0.20-0.49 U/L
Heparin  is  used  widely  for  the  prevention and 
treatment of thromboembolic diseases, during  
procedures  of  haemodialysis  and cardiopulmonary 
bypass  surgeries.  Two types of heparin preparations 
widely in use today are unfractionated heparin (UFH) 
and low molecular weight heparin (LMWH). The 
inconvenience and limited precision of monitoring of 
(UFH) therapy has contributed to the increasing use of 
LMWH preparations. The pharmacokinetic properties 
of LMWH are different from (UFH) and allows for 
easily monitored anticoagulant effects of a given dose. 
Monitoring is, however, recommended in clinical 
settings like renal insufficiency, obesity, paediatric 
patients and those on prophylactic anticoagulant 
therapy in conditions like malignancy or anti-
phospholipid syndrome. Anti-factor Xa assay is used 
to monitor LMWH therapy.
Principle of anti-factor Xa is based on the fact 
that both factor Xa and antithrombin III are added 
in excess amounts to the test plasma and the 
residual factor Xa activity is inversely proportional 
to the heparin concentration. The test is based 
on the assumption that the patient has a normal 
concentration of antithrombin III.
The test is performed by adding a known amount 
of factor Xa and antithrombin to the plasma of 
the patient. If heparin or LMWH is present in the 
patient plasma, it will bind to antithrombin and 
inhibit factor Xa. The amount of residual factor Xa 
is inversely proportional to the amount of heparin 
in the plasma. The amount of residual factor Xa is 
detected by adding a chromogenic substrate that 
resembles the natural substrate of factor Xa. Factor 
Xa cleaves the chromogenic substrate, releasing 
a coloured compound that can be detected by 
a spectrophotometer. Results  are  reported  as 
anticoagulant  concentration  in  anti-factor  Xa units/
ml, such that high anti-factor Xa values indicate 
high  levels  of  anticoagulation. Deficiencies of 
antithrombin in the patient do not affect the assay, 
because excess antithrombin is provided in the 
reaction.
Specimen is collected in sodium citrate bottle (blue 
top) about four hours after subcutaneous injection 
Anti-factor Xa Assay
Dr Natasha Ali
Haematology
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Causes of Sub-Therapeutic Anti-factor Xa Level
1. Specimen drawn at incorrect time (collection  
 times are four hours after injection of LMWH,  
 six hours after injection of danaparoid).
2. Specimen transportation time longer than two 
 hours.
3. Patient receiving prophylactic dose, therefore,  
 therapeutic range is not applicable and anti-  
 Xa level is actually appropriate for dose.
Causes of Supra Therapeutic Anti-factor Xa Level
1. Renal failure (with LMWH or danaparoid) 
 because of decreased renal clearance.
2. Heparin contamination, if specimen was 
 drawn from an IV heparinised line. 
hospitals.aku.edu/Karachi/clinical-laboratories
